Integra LifeSciences Holdings Corporation

Healthcare · Medical - Devices

Overall research band Very weak

Quality Very weak

Valuation Very weak

Balance sheet Very weak

Market confirmation Weak

One-minute company read

What this report can tell you now

What the company does

Integra LifeSciences Holdings Corporation is a medical technology company headquartered in Princeton, New Jersey, specializing in the creation, production, and global distribution of advanced surgical implants and instruments. The company operates through two main segments: Codman Specialty Surgical, which provides neurosurgical and neuro-critical care products such as tissue ablation equipment, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, cranial stabilization devices, surgical headlamps, and asset management software; and Tissue Technologies, which focuses on regenerative technology products for acute and chronic wound treatment, surgical tissue repair, hernia repair, peripheral nerve protection and regeneration, tendon reconstruction, bone grafting, and reconstructive surgery. Integra serves hospitals, surgical centers, dental, podiatry, and veterinary practices, distributing its products internationally through direct sales forces and other channels to a broad range of healthcare providers.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC2.0%Model input; read with the evidence status and period context.

Operating margin4.2%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years1.5%Model input; read with the evidence status and period context.

FCF margin-2.8%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.